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A B S T R A C T
Purpose
The Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial included a prospectively
planned pathology substudy testing the predictive value of progesterone receptor (PgR) expres-
sion for outcome of estrogen receptor–positive (ER-positive) early breast cancer treated with
exemestane versus tamoxifen.
Patients and Methods
Pathology blocks from 4,781 TEAM patients randomly assigned to exemestane versus tamoxifen
followed by exemestane for 5 years of total therapy were collected centrally, and tissue
microarrays were constructed from samples from 4,598 patients. Quantitative analysis of
hormone receptors (ER and PgR) was performed by using image analysis and immunohistochem-
istry, and the results were linked to outcome data from the main TEAM trial and analyzed relative
to disease-free survival and treatment.
Results
Of 4,325 eligible ER-positive patients, 23% were PgR-poor (Allred  4) and 77% were PgR-
rich (Allred  5). No treatment-by-marker effect for PgR was observed for exemestane
versus tamoxifen (PgR-rich hazard ratio [HR], 0.83; 95% CI, 0.65 to 1.05; PgR-poor HR, 0.85;
95% CI, 0.61 to 1.19; P  .88 for interaction). Both PgR and ER expression were
associated with patient prognosis in univariate (PgR HR, 0.53; 95% CI, 0.43 to 0.65; P  .001;
ER HR, 0.66; 95% CI, 0.51 to 0.86; P  .002), and multivariate analyses (P  .001 and
P  .001, respectively). A trend toward a treatment-by-marker effect for ER-rich patients
was observed.
Conclusion
Preferential exemestane versus tamoxifen treatment benefit was not predicted by PgR expres-
sion; conversely, patients with ER-rich tumors may derive additional benefit from exemestane.
Quantitative analysis of ER and PgR expression provides highly significant information on risk of
early relapse (within 1 to 3 years) during treatment.
J Clin Oncol 29:1531-1538. © 2011 by American Society of Clinical Oncology
INTRODUCTION
For decades, tamoxifen remained the gold stan-
dard for adjuvant endocrine therapy for estrogen
receptor–positive (ER-positive) and/or progester-
one receptor–positive (PgR-positive) early breast
cancer. Patients with ER-positive tumors who received
tamoxifen for 5 years experienced significantly re-
duced rates of recurrence and death.1 However, a
significant group with hormone receptor–positive
(HRec-positive) tumors exhibited resistance, either
acquired or de novo, to tamoxifen therapy.2,3 Sev-
eral resistance mechanisms are hypothesized, in-
cluding signaling via human epidermal growth
factor receptor (EGFR) homolog 2 (HER2), EGFR/
HER1, and HER34-7 signaling pathways,8,9 or loss of
ER-mediated gene regulation.10,11 Differential sen-
sitivity to endocrine agents (eg, aromatase inhibitors
[AIs] v tamoxifen) has been linked to bypassing re-
sistance pathways.12-14
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The third-generation AIs—anastrozole, exemestane, and
letrozole—induce nearly complete suppression of circulating estro-
gens in postmenopausal women. In randomized clinical trials in post-
menopausal women with HRec-positive early breast cancer,13-15 AIs
significantly improved disease-free survival (DFS) compared with ta-
moxifen. In the Intergroup Exemestane Study (IES), patients switch-
ing to exemestane after 2 to 3 years of tamoxifen experienced
significant improvements in outcome compared with those remain-
ing on tamoxifen.16 Additionally, patients with PgR-negative tumors
in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial
appeared to gain significant additional benefit from anastrozole ver-
sus tamoxifen.17
The Tamoxifen and Exemestane Adjuvant Multinational
(TEAM) trial compared the efficacy of exemestane versus sequential
therapy of tamoxifen followed by exemestane for 5 years of total
adjuvant endocrine therapy.18 TEAM provided an ideal setting to test
hypotheses regarding primary tamoxifen resistance. PgR is considered
“time-dependent” because the impact of low PgR expression on re-
lapse risk in ER-positive, tamoxifen-treated patients with breast can-
cer is confined to the first 3 years of endocrine therapy.10 The study
presented here addresses the hypothesis that low PgR expression pre-
dicts clinical benefit for patients receiving initial AI treatment rather
than tamoxifen in the first 2.75 years of therapy.17 The translational
aspect of TEAM is unique because the hypotheses were prospectively
defined and powered at the time of study design.
PATIENTS AND METHODS
Design
The TEAM trial is a multinational, randomized, open-label, phase III
trial in postmenopausal women with HRec-positive early breast cancer.
Women were randomly assigned to receive exemestane 25 mg once daily or
tamoxifen 20 mg once daily for the first 2.5 to 3 years followed by exemestane
(for a total of 5 years of treatment). Coprimary end points were DFS at 2.75 and
5 years. This study complied with the Declaration of Helsinki, individual
independent ethics committee guidelines, and the International Conference
on Harmonization and Good Clinical Practice guidelines. All patients pro-
vided informed consent.
One hypothesis tested in the TEAM pathology substudy was that initial
therapy with exemestane is superior to tamoxifen in patients with ER-positive
and PgR-negative or PgR-poor tumors. The prospectively powered outcome
analysis compared high PgR expressers (approximately 75% of tumors) with
low PgR expressers (approximately 25%). This analysis was planned for 2.75
years after last patient enrollment and was not event driven. By using a two-
sided  .05 and assuming a hazard ratio (HR) of 1.9 and PgR-poor preva-
lence of 25%, a sample size of 4,000 patients gave 90% power to detect a
treatment-biomarker interaction.
Patients
Inclusion and exclusion criteria differed slightly by participating coun-
try.18 Eligible patients were postmenopausal with HRec-positive resectable
breast cancer (defined locally), with histologically or cytologically confirmed
T1-3 N0-2 M0 breast adenocarcinoma and adequate surgical resection fol-
lowed by radiotherapy and/or adjuvant chemotherapy if indicated. Five of
nine countries that participated in the TEAM trial (United Kingdom/Ireland,
the Netherlands, Belgium, Germany, and Greece) provided tumor samples for
this substudy.
Staining Methodology
Briefly, tissue blocks were received at the central laboratory, logged,
reviewed for sufficient tissue, subjected to pathology quality assurance and
tissue marking, and had six cores extracted and placed on six replicate tissue
microarrays (TMAs). Standard immunohistochemical techniques were used
to stain TMAs for ER (Clone 6F11; Novocastra, Newcastle, United Kingdom)
and PgR (Clone PgR636, DAKO, Cambridge, United Kingdom). Assays were
performed by using a single batch of antibody and reagents, with incubations
rigorously controlled for temperature. Each run included a quality-control,
six-sample TMA with various ER and PgR expression, and runs were accepted
only if histoscore inter-run variation was 15%. Staining and scoring of ER
and PgR by using TMAs and the Ariol SL-50 image analysis system (Genetix,
New Milton, United Kingdom) were previously validated.19 Samples were
stained in sextuplet (6  0.6 mm2 cores). Slides were counterstained; each
TMA section was scanned, mapped to positional map, and individually as-
sessed for tumor content (tumor areas were marked and checked and a second
pathology quality-assurance assessment was performed). The actual number
and percentage of cells in each category were recorded, with a minimum of 100
tumor nuclei per patient required for eligibility. Nuclear HRec staining was
assessed by using a previously validated scoring algorithm,19 with nuclei
grouped into categories of negative, weak (1), moderate (2), and strong
(3) nuclear staining, to generate a continuous histoscore (range, 0 to 300).
The histoscore was calculated by multiplying the sum of the percentage of
weakly stained cells times 1, the percentage of moderately stained cells times 2,
and the percentage of strongly stained cells times 3.
Statistical Analysis
All analyses were performed for DFS (censored at 2.75 years), defined as
time from random assignment to earliest documentation of disease relapse (ie,
primary tumor recurrence [locoregional or distant] and ipsilateral/contralat-
eral breast cancer) or death from any cause. Cox proportional hazards regres-
sion models were used to assess prognostic and predictive values of PgR and
ER expression. Interactions between treatment arms and PgR or ER expression
levels were evaluated by examining the log likelihood ratio statistic. Both PgR
and ER were included as binary covariates for Allred score (PgR-poor 4 v
PgR-rich 5; ER-poor 6 v ER-rich 7). The PgR cutoff was informed by
our previous data10; the ER cutoff was informed by the TransATAC study.20
Adjusted analyses were performed for patient age (continuous variable), tu-
mor size ( 2 cm v 2 cm), nodal status (negative v positive), and histologic
grade on an intent-to-treat basis. Continuous HRec expression data were
checked for nonlinearity by applying a log transformation and assessing
changes in Akaike information criterion between univariate Cox proportional
hazards models of transformed and untransformed data.21 The best-fitting
model was used to plot the predicted log HR and 95% CI values against
quantitative HRec expression. All data were analyzed by using SAS/STAT
statistical software (SAS Institute, Cary, NC).
A prognostic (risk) score (scale, 0.0 to 4.0) was derived based on prog-
nostic modeling of ER and PgR expression as continuous variables; tumor
grade, tumor size, and nodal status as dichotomous variables; and age as a
continuous variable. Each variable was assessed for nonlinearity by using log
transformations and fractional polynomials; factors considered significant at
 .1 were included in the model. Individual patients’ prognostic factors were
multiplied by the coefficients defined in the multivariate prognostic model
as follows: score  (PgR histoscore  0.00372)  (ER histoscore 
0.00227)  ([age-38]  0.67)  (grade  0.38992)  (T size 
0.45302)  (nodal status  0.61221), where age-38 represents age at
diagnosis minus 38 years, and T size represents pathologic tumor size.
Patients’ scores were plotted against their survival estimate as calculated
by the Cox proportional hazards model, and results were split by randomized
treatment. The number needed to treat (NNT) to prevent one recurrence was
calculated as described previously.22
RESULTS
Study Population
Eligible samples (n  4,781) were received and analyzed by
country (samples received/randomly assigned patients) from United
Kingdom/Ireland (1,097/1,275; 86.0%), the Netherlands (2,722/
2,753; 98.9%), Belgium (122/414; 29.5%), Germany (745/1,471;
Bartlett et al
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50.6%), and Greece (95/207; 45.9%). In total, 4,598 samples were
suitable for TMA construction and ER and PgR staining. Following
staining, 219 samples contained 100 stained tumor nuclei, 42 sam-
ples were ER-negative (of which 28 were PgR-positive), and 12 sam-
ples were ineligible for other reasons. For the remaining samples, a
median of  1,200 cells per tumor were analyzed. Only 14 ER-
negative/PgR-negative patients (0.3%) were identified in the pathol-
ogy cohort, and 4,325 eligible ER-positive patients (87% of target
population) were analyzed. Patient tumor characteristics were similar
among samples from the pathology subset and all patients from coun-
tries participating in the pathology substudy, but there were slight
differences between these two groups and the entire TEAM popula-
tion regarding tumor size, nodal status, and grade (Table 1). Most
tumors (87.3%) in the pathology substudy had ER Allred scores of 7 to
8, with only 12.7% having Allred scores  6. In total, 3,341 tumors
(77.2%) were PgR-rich (Allred score, 5 to 8) and 984 (22.8%) were
PgR-poor (Allred score, 0 to 4).
Efficacy
In the pathology substudy, 397 DFS events were recorded
within 2.75 years of random assignment with a trend toward a DFS
benefit of exemestane compared with tamoxifen (HR, 0.84; 95%
CI, 0.69 to 1.02; P .078). The HR for the DFS benefit of exemes-
tane within the whole trial was similar to that observed for the
pathology subgroup (HR, 0.89; 95% CI, 0.77 to 1.03; P  .12).
Overall, the pathology substudy population was well matched to
the patient population from which the samples were collected, but
the patients were of higher risk than those in the United States
(Table 1). Expression of PgR was a significant prognostic indicator
in univariate analyses (PgR-rich v PgR-poor; HR, 0.53; 95% CI,
0.43 to 0.65; P .001; Fig 1A) and adjusted multivariate analyses
(HR, 0.54; 95% CI, 0.44 to 0.68; P .001). Univariate Cox regres-
sion with PgR expression as a continuous variable yielded an HR of
0.81 (95% CI, 0.77 to 0.86; P  .001) per 50-unit increase of PgR
expression (eg, PgR histoscore of 50 was associated with a 19%
reduction in DFS compared with histoscore of 0). Nonlinearity
between PgR expression and DFS was investigated but not con-
firmed, and PgR was therefore modeled under the assumption of
linearity (Fig 1B). Multivariate Cox regression analysis, including a
treatment-by-marker analysis, showed no evidence that PgR ex-
pression was predictive of a differential DFS benefit for exemestane
compared with tamoxifen (PgR-poor HR, 0.85; 95% CI, 0.61 to
1.19; PgR-rich HR, 0.83; 95% CI, 0.65 to 1.05; test for interaction
P  .88; Fig 2). Analyses were also performed by using the actual
switch point rather than 2.75 years. The interaction for differential
benefit of treatment was not statistically significant (PgR-poor
HR, 0.94; 95% CI, 0.65 to 1.35; PgR-rich HR, 1.12; 95% CI, 0.85
to 1.49; test for interaction P  .7); hence the conclusions re-
main unchanged.
A similar analysis confirmed that moderate to poor ER expres-
sion (Allred score  6) was associated with a significantly worse
prognosis than ER-rich tumors (Allred score 7) in both univariate
(ER-rich v ER-poor HR, 0.66; 95% CI, 0.51 to 0.86; P .002; Fig 3A)
and multivariate regression analysis (adjusted HR, 0.65; 95% CI, 0.50
Table 1. Patient and Tumor Characteristics
Characteristic
Subset of Pathology
Samples Received
(n  4,325)
Pathology Substudy
Population
(n  6,120)
TEAM Study
ITT Database
(n  9,766)
No. % No. % No. %
Age, years
 60 1,393 32 2,085 34 3,348 34
 60 2,932 68 4,035 66 6,418 66
Nodal status
Positive 2,602 60 3,494 57 4,585 47
Negative 1,713 40 2,604 43 5,113 52
Unknown 10  1 22  1 68 1
Tumor size, cm
 2 2,120 49 3,028 50 5,697 58
 2 2,197 51 3,027 50 4,047 41
Unknown 8  1 20  1 20  1
Grade
1 486 11 616 10 1,677 19
2 2,199 51 3,166 52 4,795 54
3 1,370 32 1,835 30 2,438 27†
ER Allred score
0-4 153 3.5 N/A N/A
5-6 398 9.2 N/A N/A
7-8 3,774 87.3 N/A N/A
PgR Allred score
0-4 984 22.8 N/A N/A
5-8 3,341 77.2 N/A N/A
Abbreviations: TEAM, Tamoxifen and Exemestane Adjuvant Multinational; ITT, intent-to-treat; ER, estrogen receptor; N/A, not available; PgR, progester-
one receptor.
Randomly assigned patients from the United Kingdom, Ireland, the Netherlands, Belgium, Germany, and Greece were included in the pathology substudy.
†Grade 3 to 4.
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to 0.85; P .001). Again, after investigating the nonlinearity assump-
tion of ER expression, univariate analysis for linearly increasing ER
histoscores as a continuous variable found a 17% risk reduction re-
lated to a 50-unit increase in histoscore (HR, 0.84; 95% CI, 0.77 to
0.91; P  .001; Fig 3B). In an unplanned analysis of the predictive
value of ER expression, a trend toward benefit in favor of exemestane
was observed (Fig 4A). Tumors with ER histoscores 190 (median,
ER-poor) had an HR for exemestane versus tamoxifen of 0.94 (95%
CI, 0.72 to 1.22; Fig 4B), whereas the HR in favor of exemestane for
ER-rich tumors (histoscore 190) was 0.73 (95% CI, 0.54 to 0.98; Fig
4C). However, adjustment for other prognostic factors did not con-
firm a significant treatment-by-marker effect (P .2). Analyses per-
formed by using the actual switch point showed that the interaction
for differential benefit of treatment was not statistically significant
(ER-poor HR, 1.13; 95% CI, 0.84 to 1.51; ER-rich HR, 0.97; 95% CI,
0.69 to 1.36; test for interaction P .5).
Prognostic Model
By combining and weighting prognostic variables shown to in-
dependently influence risk of early relapse (within 2.75 years), a risk
score integrating ER and PgR expression level, age, tumor grade,
tumor size, and nodal status was derived and plotted against risk of
recurrence in each treatment arm (Fig 5). In this model, lower levels of
ER and PgR expression correspond with a higher risk score, as do
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Fig 1. Progesterone receptor (PgR) as a prognostic marker of disease-free
survival by (A) Allred score ( 4 v 5) and (B) quantitative PgR expression plotted
versus log hazard ratios (HRs); gray line represents PgR histoscore versus hazad
ratio; blue lines represent 95% CI of estimate. T, tamoxifen; E, exemestane. (*)
Per 50-unit increase in PgR.
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Fig 2. Progesterone receptor (PgR) is not predictive of exemestane (E) versus
tamoxifen (T) benefit. (A) Hazard ratio (HR) by Allred score ( 4 [PgR poor] v  5
[PgR rich]); (B) exemestane versus tamoxifen in PgR-poor, and (C) PgR-rich
tumors. (*) Test for interaction by PgR staining.
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increased tumor size and grade, node positivity, and patient age. In the
highest-risk population (risk score, 3.0), the NNT with exemestane to
prevent one recurrence was 12.5. Conversely, in patients with a low
risk of early recurrence (risk score, 0.1), the absolute benefit derived
with initial exemestane was minimal (NNT 167).
DISCUSSION
The TEAM pathology substudy included the largest prospective bio-
marker analysis within an adjuvant AI trial, rejecting the a priori
hypothesis that low PgR expression might predict improved benefit
from AI treatment. Both PgR and ER expression levels were quan-
titatively associated with DFS. The relative risk of relapse increased
proportionally with decreasing expression of either receptor, dem-
onstrating a concentration effect of HRec expression on prognosis
(Figs 1B and 3B). However, PgR status did not predict additional
benefit of exemestane versus tamoxifen (P .88 for PgR-rich v PgR-
poor interaction with treatment). This prospective analysis demon-
strates that PgR is strongly prognostic for patients treated with
endocrine agents (either AIs or tamoxifen) but does not provide a
marker to select patients who derive additional benefit from AIs over
tamoxifen when analyzed as a dichotomous variable. These data are
consistent with the analysis of PgR in the TransATAC23 and Breast
International Group (BIG 1-98)24-26 studies, but contrast with the
primary ATAC trial report.17 The prospectively powered and planned
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Fig 3. Estrogen receptor (ER) as a prognostic disease-free survival marker by (A)
Allred score ( 6 v  7) and (B) quantitative ER expression plotted against log
hazard ratios (HRs); gray line represents ER histoscore versus hazard ratio; blue
lines represent 95% CI of estimate. T, tamoxifen; E, exemestane. (*) Per 50-unit
increase in ER.
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Fig 4. Estrogen receptor (ER) as a predictive marker for exemestane (E) versus
tamoxifen (T) treatment. (A) Hazard ratio (HR) by histoscore ( 190 [ER-poor
tumors] v  190 [ER-rich tumors]); (B) exemestane versus tamoxifen in ER-poor
and (C) ER-rich tumors. (*) Test for interaction by ER staining.
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analysis within the TEAM study provides high-level evidence to refute
the original observation from the primary ATAC report that low PgR
expression is a predictive biomarker for initial therapy selection with
AIs versus tamoxifen.17 When viewed in the context of other analyses
and translational studies, current evidence supports the conclusion
that the relative benefit from AIs is similar for tumors that express low
versus high levels of PgR.
Nonetheless, ER and PgR are significant prognostic factors in
postmenopausal patients with early breast cancer who are receiving
adjuvant endocrine therapy.10,27-30 Recent evidence, including our
study, suggests that PgR as a prognostic marker is both time- and
concentration-dependent.10 The current study produced highly con-
sistent quantitative HRec expression data by using image analysis and
robustly quality-assured immunohistochemistry, allowing us to dem-
onstrate a significant link between recurrence risk and quantitative
changes in HRec expression, irrespective of endocrine treatment mo-
dality. These and similar analyses31,32 argue strongly against the cur-
rent practice of dichotomizing patient risk of recurrence relative to
specific HRec expression cutoffs. Allred scores of 2 to 4 are widely used
to discriminate between patients who are likely to respond to hor-
mone therapy and those who are not, but little attention is paid to
markedly varying risk of relapse across the 80% to 85% of ER-positive
patients or the  75% of PgR-rich patients demonstrated herein.
Although patients derive approximately equally proportional benefit
from exemestane in PgR-poor and PgR-rich tumors, the strong prog-
nostic influence of HRec expression may affect the absolute benefit
observed in different subgroups of HRec-positive patients. A 10-fold
reduction in risk of relapse for ER-moderate versus ER-rich patients
with a constant proportional benefit from AIs versus tamoxifen sug-
gests a 10-fold increase in absolute NNTs to prevent one recurrence.
Such exploratory analyses, which were also performed in the BIG 1-98
and ATAC trials, imply that many more patients in low-risk groups
with high HRec expression are exposed to the risk of adverse effects
relative to the numbers that benefit compared with higher-risk groups
with low HRec expression. This observation clearly underpins the
continuing use of patient risk stratification in many local and national
guidelines for AI use. By modeling the relative contribution of HRec
expression with clinical and pathologic variables (eg, age, nodal status)
within the TEAM pathology cohort, we extended this risk stratifica-
tion to produce a risk estimate for individual patients within the first
2.75 years of treatment with either exemestane or tamoxifen. At higher
risk scores, the absolute DFS benefit of exemestane versus tamoxifen
was more apparent, whereas at lower risk scores, the absolute benefit
was modest.
In an unplanned analysis, quantitative image analysis that used
median ER histoscores, following the categorization used in previ-
ously published TransATAC data, suggested that high expression of
ER is predictive of preferential benefit for exemestane compared with
tamoxifen. Although this interaction was not significant (P .3), the
HRs and 95% CIs (HR, 0.72; 95% CI, 0.53 to 0.97 and HR, 0.92; 95%
CI, 0.70 to 1.20) for ER-rich and ER-poor patients, respectively, indi-
cated a potential clinical significance of quantitative ER levels for
selection of endocrine therapies. Similar results were reported in the
TransATAC study, in which a significant relationship between in-
creasing ER expression and time to relapse was reported only for
patients treated with anastrozole (P  .001) but not tamoxifen
(P .78).23 These results conflict with observations from neoadjuvant
studies,33 which showed that AIs appeared to provide additional ben-
efit in HRec-poor patients. The observations in the TEAM and ATAC
studies suggest that more effective endocrine agents could have pro-
portionally greater impact on highly endocrine-responsive tumors
rather than on less endocrine-responsive tumors as previously be-
lieved.23 Therefore, current data confirm a strong prognostic effect (ie,
decreased risk of relapse as HRec expression increases) and a potential
predictive effect of HRec expression (ie, increased benefit of exemes-
tane as ER expression increases). Statistical modeling of this potential
effect is complicated by possible interactions between ER and PgR
expression and because the fewest events (ie, low recurrence risk) are
observed at the point of potential maximum divergence between
exemestane and tamoxifen treatment. These results, however, were
derived from retrospective, unplanned analyses and are not sufficient
to alter current clinical practice but must be regarded as hypothesis
generating. Future modeling, perhaps in a meta-analysis of all AI trial
pathology archives, is required to explore this potential interaction
between the prognostic and predictive impact of HRec expression.
The TEAM pathology substudy provides, to the best of our
knowledge, the only prospectively planned and powered analysis of
the interaction between PgR and efficacy of exemestane versus tamox-
ifen as initial endocrine therapy. By using expression scores derived
from quantitative image analysis for HRec expression in analyses that
were not preplanned, this study further demonstrated that patients
derive benefit from endocrine therapies directly proportional to their
relative risk, which is strongly influenced by quantitative changes in
ER and PgR expression as well as other clinical and pathologic features.
In an unplanned analysis, patients with breast tumors expressing high
ER levels were shown to potentially benefit preferentially from initial
treatment with exemestane over tamoxifen. Validation of these obser-
vations in a meta-analysis of data from all AI translational studies may
provide evidence of a clinically useful marker approach to patient
stratification for early versus delayed treatment with AIs.
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